Haisight Medical's Breakthrough in Domestic Minimally Invasive Glaucoma Solutions: Pioneering China’s MIGS Innovation

The eyes are an important part of the human body for obtaining external information.Sensory Organs, approximately80%The external information is obtained through the eyes, and its importance goes without saying.

With the population of ChinaStructuralAging、Improper living habits, etc.MoreThe influence of factors,In ChinaThe incidence of eye diseases such as glaucoma, cataracts, and macular degeneration continues to rise.

Among them, glaucoma, as a worldwideThe Second Leading Cause of Blindness and the Primary Irreversible Blinding Eye Disease，Because of itsInsidious onset、Atypical clinical symptoms,Early StageMissed Diagnosis、Higher misdiagnosis rate. And as a progressive, currently incurable disease, glaucomaCourse of diseaseLater willAccompanied by elevated intraocular pressure and optic nerve atrophy,Bring irreversibleBlindness。 According to the "Chinese Glaucoma Guidelines (" published by the Ophthalmology Society of the Chinese Medical Association,2020）》Display, at this stage, China has more than2000Ten thousand glaucoma patients, among whichExceed1/4ThePatientBlindness。

In addition, compared with the diagnosis and treatment of ophthalmic diseases such as cataracts and macular lesionsMeans, GlaucomaDiagnostic methods and progress are relativelySlow. AndSimilar to most chronic diseases, in current clinical practiceTargetingGlaucomaThere is no cure yet.However, with early detection and proper treatment, the vast majority of patients can maintain their vision for life. Therefore, the prevention of blindness from glaucoma must emphasize early detection, early diagnosis, and early treatment.

Faced with such a huge and unmet demand in clinical practice, relatedIn the field ofPractitionersNever Stop Pursuing BetterSolutionExploration. Among them, minimally invasive glaucoma surgery(Micro-Invasive Glaucoma Surgery, MIGS) BecauseItsMinimally invasive, complicationsFew、Short learning curve for doctorsSuch advantages，InEurope and AmericaPresentationRapid DevelopmentThe trend,At the same time, it has also attracted numerous innovations., EntrepreneurshipPatientFocusHere.Located in SuzhouBiobayHSGD (Suzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as"HSGD" is precisely one of the outstanding performers.

Recently, VCBeat communicated with HSGD's founding team.TeamThe dialogue attempts to understand its layout and innovation in the glaucoma treatment field and even the entire ophthalmology field.

HSGDFounding TeamNotFirst Entrepreneurship,Yes"The 'Double Creation' Strategy in the National Development Process"Veteran Entrepreneur.

2014Year,In China"Mass Innovation and Entrepreneurship" CrazeBelow,Researchers and innovation teams from various fields are actively embarking on the path of transforming scientific research achievements, attempting to bring innovative technologies from the laboratory to the market.In this wave,AndNumerousResearchAttributeEntrepreneurshipPatientSimilar，Alma Mater、500The founding team of Hisilicon, a strong corporate R&D center, is alsoDifferentActively explore and attempt in the field, In this process,The team also has a profoundRecognizedWhat Kind of Technological Innovation Is Clinically Needed?。

Therefore, in“SecondaryEntrepreneurship"During the process, the team also realizedTrueOpportunityMust aim at the clinical "UnmetHardDemand"。TeamSecond Entrepreneurship，Be extremely cautious in choosing the track.。The first is related procedures inThere is a huge demand and value in clinical practice; secondlyProduct development involves hardcore technology that needs to be challenged.High thresholdThe moat is deep;Next,YesThe team's accumulation and experience canDeep cultivation of capabilities in the selected track。

Under the influence of this shift in thinking,TeamStartFrequent and ClinicalDepartment'sFrontline DoctorsFriends gather together to discuss the clinical status quo.Encountered problems,Research ComparisonDevelopment Trends in Various Medical Device Fields at Home and Abroad,Ultimately focusing on the field of ophthalmic devices andMinimally InvasiveExploration of Glaucoma Treatment Solutions。

"China has over 2 million glaucoma patients00010,000 people,40Years old and aboveBlindness rate exceeds30%, with the aging population and the excessive use of eyes caused by the popularity of electronic products,It can be expected that the incidence of glaucoma will be higher.，Limited by the physiological structural characteristics of the eyes, ophthalmic surgical instruments require high precision, which is also critical in clinical practice.Pursuing Smaller Incisions and Ultra-High Precision Instrument Dimensions"Control." The HSGD team said in an interview.

2020，TeamOfficially EstablishedHSGDHSGD (Suzhou) Biomedical Technology Co., Ltd.`, Focusing on Glaucoma`Micro in the Eye FieldCreative Surgical SolutionsFull Pipeline Product Development of the Solution，Firmly OpenNewJourney。

During the exchange with the founding team of HSGDMiddle，The author alsoComparison of Minimally Invasive Interventions in ChinaCoronaryThe Development Process of Stent Systems.

2003Year，The number of coronary heart disease patients in China has exceeded20 million people, however, only 70,000 to 80,000 patients undergo coronary angiography each year, and only 20,000 to 30,000 receive interventional treatment.。At that time, Coronary Heart DiseaseClinicalTreatmentMeansMainly drug treatment and surgical bypass surgeryDrug therapy is the cornerstone of treatment for coronary heart disease, not only alleviating angina symptoms and stabilizing the condition, but also certain medications can slow down or mitigate the progression of coronary atherosclerosis.。

In contrast, surgical bypass surgery involves opening the chest and using a segment of the patient’s own vein or artery to connect the two ends of the narrowed or occluded coronary artery, establishing a bypass that restores coronary blood flow.

With the development of minimally invasive interventionalThe application of equipment products in clinical practice in China,Coronary Stents and Related ProductsWith the advantages of short treatment duration, minimal trauma, and significant efficacy,Rapidly developed into a mainstream procedure，From every year2Ten Thousand CasesStarting, gradually developing to the presentEvery yearUp to100Ten Thousand CasesCoronary Stent Surgery, Annual Clinical Usage of Coronary StentsRecently20010,000 sets，Increased by dozensTimes,Gave rise to a group of listed companies such as LePu and MicroPort., with a market size of up to200100 Million。And during the same period, coronary artery bypass surgery in ChinaOnly from 4000ExampleFrom left to right, up to now every yearLess than 50,000Example.

Currently,GlaucomaClinicalTreatment methods,Very much like20Coronary Heart Disease Before the New Year，2000Millions of patients, compared to coronary heart diseaseHigherMortality Rate, Glaucoma also hasA large proportion ofIrreversibleBlindness rate. AndIn the current stage of glaucoma clinical treatment,Also with20Year-endCoronary Heart DiseaseDevelopment Stage of Treatment MethodsSimilarly,MainForTwo treatment methods: medication and surgery。In the early stages, drug intervention is primarily used, while in the later stages, surgical methods are often employed to control intraocular pressure.HoweverThese twoThese therapies all have certain limitations.，Drug therapy has a variety of systemic and local adverse reactions.And medication adherence issuesExternal，Also requires patients to take medication for a long term or lifelong.。

AsGlaucoma SurgeryTreatment FundStandardOfTrabeculectomy,Application in the Treatment of Coronary Heart DiseaseCoronary artery bypass surgery, likewise, existsDoctorLong learning curve, vision loss, cataracts, infection, mild ptosis (drooping eyelids), etc.More complications,The Possibility of Secondary SurgeryLow-level Issues。

WithMedical Device IndustryHigh-precision processing technology andProcessing CapacityImprove，Minimally Invasive Glaucoma SurgeryMIGSInstrumentBegan to be appliedClinicalPractice, rapid development.MIGSInstrument with itsAdvantages such as minimal incisions, effective pressure reduction, high safety, rapid healing, and reduced risk of complications have gradually become a hot topic in the field of glaucoma treatment.

Currently,China has not yet had a domestically produced minimally invasive glaucoma surgery product officially approved for marketing, at this stage.XENDrainage Tube This Imported Product，It is the only minimally invasive glaucoma surgery product in China that uses an internal approach through the subconjunctival pathway. There is a significant lack of domestically produced minimally invasive glaucoma surgery products.From this perspective, HSGD's layout in the field of minimally invasive glaucoma surgery is expected to accelerate the compensation for the shortcomings and gaps in China's minimally invasive glaucoma surgery products.

According to reports, in the field of minimally invasive glaucoma surgery, HSGD has formed a relatively complete product solution for minimally invasive glaucoma surgery based on the early, middle, and late stages of glaucoma progression.。Among them, HSGD targets the open-angle glaucoma condition.，The Developed Implantable StentMicroCOGOThe peripheral diameter is less than300Micrometers, the minimum diameter of the internal pathway design is evenReach approximately30-40The scale of micrometers fully reflects HSGD's capabilities at the micrometer level.3DCapabilities and Foundations of Ultra-Precision Micromachining。

As one of the most complex and sophisticated organs in the human body,The product development of implantable devices is extremely challenging, and most related research in the past...And TryFen Fen Zhe Ji，Mostly restrictedFor SupplyThe shortcomings and gaps in the ultra-fine precision processing capabilities of the chain.

In order to solve this problem, inCompany EstablishmentPrevious Technical Demonstration Phase，HSGD Founding TeamConvenient andProf. Sun Xinghuai's team from Shanghai ENT Hospital and other frontline cliniciansCarried outCloseof Cooperation、Communicate fully to understand clinical needs and doctors' operational habits.HSGDIn the team,GatheredFrom the USDunForce, Philips and other crossIn ChinaR&D talents ensure the technical advantages in product development.

Thanks to the outstanding performance and technical foundation of the company's products, less than a year after its establishment, HSGD successively completed the angel round andpre-ARound of financing, andRapidEstablished inNantongPrecision Machining and Manufacturing CenterAndLocated inShanghaiTheR&D Center, for the subsequent mass production of the productLay the FoundationFoundation.

Currently，HSGD has also plannedWithin the yearUnder its umbrellaMultipleProductChinaMulticenter Clinical Trial,AndIn ChinaMore than 10Large tertiary hospitalsExpandCooperation.

Except for advancementClinical Progress and Registration of Existing ProductsOutside of work, in terms of product development, HSGD will further enrich its minimally invasive glaucoma surgery product line. According to reports, HSGD is currently planning to attempt the development of drug-device combination products for glaucoma.Early ScreeningIntelligenceHardwareThe development of products, introducing more innovative products with significant implications for glaucoma diagnosis and treatment.

Based on the existing accumulation of underlying technology, HSGD will also continue to advance in more...Ophthalmology FieldImportMonopolisticProductField ProgressBreaking the Ice. InDevelopmentOfIn the process, human resourcesAlways the development of HSGDPrimaryDemand,HSGD also hopes to have moreExcellentTalent Joins the Team。

"With every bit of our"Strive to care for every glimmer of hope for patients." This is not only the vision of HSGD but also its original intention.